APRILIAH (Aprogen Phase III Clinical Trial to Compare Efficacy, Safety, and Immunogenicity of AP063 in Subjects with HER2+ Breast Cancer)

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506975-83-00

Acronym

AP063-003

Enrollment

Registered

2024-03-08

Start date

Unknown

Completion date

2025-04-17

Last updated

2024-07-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HER2-positive metastatic breast cancer (MBC) and early breast cancer (EBC)

None listed

Sex/Gender

All

Age

18 Years to No maximum

Poland, Romania

None listed

Source: EU CTIS · Data processed: Feb 4, 2026